Evidence map›Paper›PMID 37377898›Full record

ArticleCancer research communications2023

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.

Vasu R Sah, Henrik Jespersen, Joakim Karlsson, Lisa M Nilsson, Mattias Bergqvist, Iva Johansson, Ana Carneiro, Hildur Helgadottir, Max Levin, Gustav Ullenhag and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02697630 (A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02697630 phase2completednot on this map

A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma

TypeinterventionalSponsorVastra Gotaland RegionRan2018 to 2023Enrolled29ConditionsMetastatic Uveal MelanomaArmsPembrolizumab, Entinostat
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Vasu R SahSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-7897-6156
Henrik JespersenDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0002-6543-5369
Joakim KarlssonHarry Perkins Institute of Medical Research, University of Western Australia, Perth, Western Australia, Australia.ORCID 0000-0001-6332-4043
Lisa M NilssonHarry Perkins Institute of Medical Research, University of Western Australia, Perth, Western Australia, Australia.ORCID 0000-0002-5222-7210
Mattias BergqvistBiovica International AB, Uppsala Science Park, Uppsala, Sweden.ORCID 0000-0002-0093-9443
Iva JohanssonDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0002-9683-4637
Ana CarneiroDepartment of Oncology, Skåne University Hospital, Lund, Sweden.ORCID 0000-0002-1818-7008
Hildur HelgadottirDepartment of Oncology, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-0735-4771
Max LevinDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0001-9676-5582
Gustav UllenhagDepartment of Radiology, Oncology and Radiation Science, Section of Oncology, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-4949-3267
Anders StåhlbergDepartment of Laboratory Medicine, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-4243-0191
Roger Olofsson BaggeSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-5795-0355
Jonas A NilssonSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-0346-6837
Lars NyDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0003-3864-5958
Sahlgrenska University Hospital · SEHarry Perkins Institute of Medical Research · AUKarolinska University Hospital · SEOslo University Hospital · NOSkåne University Hospital · SEUppsala University · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed. Patients and Methods: We previously reported that patients treated with the PD-1 inhibitor pembrolizumab and the histone deacetylase inhibitor entinostat in the PEMDAC trial, experienced clinical benefits if their tumor originated from iris or was wildtype for Results: Durable responses were observed in 4 patients, with additional 8 patients exhibiting a stable disease. The median overall survival was 13.7 months. Grade 3 adverse events were reported in 62% of the patients, but they were all manageable. No fatal toxicity was observed. Activity of thymidine kinase 1 in plasma was higher in patients with stable disease or who progressed on treatment, compared with those with partial response. Chemokines and cytokines were analyzed in plasma. Three chemokines were significantly different when comparing patients with and without response. One of the factors, CCL21, was higher in the plasma of responding patients before treatment initiation but decreased in the same patients upon treatment. In tumors, CCL21 was expressed in areas resembling tertiary lymphoid structures (TLS). High plasma levels of CCL21 and presence of TLS-like regions in the tumor correlated with longer survival. Conclusions: This study provides insight into durable responses in the PEMDAC trial, and describes dynamic changes of chemokines and cytokines in the blood of these patients. Significance: The most significant finding from the 2-year follow-up study of the PEMDAC trial was that high CCL21 levels in blood was associated with response and survival. CCL21 was also expressed in TLS-like regions and presence of these regions was associated with longer survival. These analyses of soluble and tumor markers can inform on predictive biomarkers needing validation and become hypothesis generating for experimental research.

Indexed as

Chemokine CCL21MelanomaChemokinesEpigenesis, GeneticFollow-Up StudiesHumansImmunotherapyUveal MelanomaUveal NeoplasmsCCL21 protein, humanChemokine CCL21Chemokines

Identifiers

PMID37377898
PMCPMC10194136
OpenAlexW4368375936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.